

ESGCT SPRING SCHOOL

BUDAPEST | 16-19 APRIL 2024

TUESDAY 16 APRIL

15:00-16:00	Registration
16:00-18:30	Workshops (40 students per workshop) Workshop 1: Connecting Science and Society: Communicating your work beyond the lab Anna Couturier, EuroGCT Workshop 2: How to write a scientific manuscript Thomas Gallagher, Human Gene Therapy Workshop 3: How to judge a scientific publication Hildegard Büning, Hanover Medical School
19:30	Meet the expert dinner @ Araz Restaurant, Continental Hotel H-1074 Budapest, Dohány utca 42-44.

WEDNESDAY 17 APRIL

08:30-09:00	Welcome Address Juan Bueren, President, ESGCT Zoltan Ivics, Spring School Host and co-organiser; President elect DG-GT Hildegard Büning, ESGCT Education & Training
09:00-10:00	Keynote INV01: Juan Bueren, Ciemat Madrid Moving from concept to clinical reality
10:00-11:30	Session 1: Gene therapy tools - insights by experts (viral vectors) INV02: Axel Schambach, Hannover Medical School What you should know about retro/lentiviral vector design INV03: Els Verhoeyen, University of Nice How to improve nature I – the next generation of lentiviral vectors INV04: Jacob Giehm Mikkelsen, Aarhus, Denmark Engineered lentivirus-derived particles for delivery of gene editing tool kits
11:30-12:00	Coffee Break



12:00-13:00	Keynote
	INV05: Fulvio Mavilio, Orchard Therapeutics
	Hematopoietic stem cell gene therapy for genetic diseases
13:00-14:00	Lunch
14:00-16:00	Session 2: Gene therapy tools - insights by experts (viral vectors)
	INV06: Hildegard Büning, Hannover Medical School
	Almost a virus – the adeno-associated virus (AAV) vector system vector design
	INV07: Alberto Auricchio, Tigem Naples
	ExpEditing AAV gene therapy
	INV08: Luk Vandenberghe, Harvard Medical School
	ĀAV as a vaccine platform
16:00-17:00	Keynote
	INV09: Gloria Gonzalez-Aseguinolaza, Fima, Pamplona
	AAV for in vivo gene editing to treat rare liver diseases
17:00-17:30	Coffee Break
17:30-19:30	Session 3: Gene therapy tools - insights by experts (non-viral vectors)
	INV10: Tristan Montier, University of Brest
	How to fine tune nanoparticles for aerosol delivery
	INV11: Raymond Schiffelers, UMC Utrecht
	Lipid nanoparticles and their applications in vaccination and beyond
	INV12: Zoltan Ivics, Paul Ehrlich Institute, Langen
	Wide awake and ready to move: non-viral genome engineering with Sleeping Beauty transposon vectors
19:45	Dinner at Ruin Bar Extra with DJ and surprise

THURSDAY 18 APRIL

09:00-10:00	Keynote INV13: Toni Cathomen, University Hospital, Freiburg Revelations in Precision: Learning from on- & off-target effects of gene editing tools
10:00-10:30	Coffee Break



10:30-12:30	Session 4: Genome and epigenome editing
	INV14: Paula Rio, Ciemat Madrid
	Gene editing with CRISPR and beyond
	INV15: Claudio Mussolino, University of Freiburg Multiplexed epigenome editing in CAR T cells
	INV16: Raul Torres, Ciemat, Madrid Prime editing, base editing etc
12:30-13:30	Lunch
13:30-15:30	Session 5: iPSC technology
	INV17: Agota Apati, Research Centre for Natural Sciences, Budapest Advancements in induced pluripotent stem (iPS) technology and two-dimensional disease models
	INV18: Kornelia Szebenyi, Research Centre for Natural Sciences, Budapest Human induced pluripotent stem cell-derived organoids for disease modelling
	INV19: Andras Nagy, Lunenfeld-Tanenbaum Research Institute, Toronto Therapeutic applications
15:30 -16:30	Keynote
	INV20: Nathalie Cartier, AskBio, Paris
	Gene therapy for CNS diseases : strategies, hurdles, results
16:30-17:00	Coffee Break
17:00-17:40	Session 6: Fighting cancer with novel weapons
	INV21: Hinrich Abken, University of Regensburg
	CARs, TRUKCKs and what is next? The evolution of CAR T cell therapy
17:40 -18:40	Keynote
	INV22: Vincenzo Cerullo, University of Helsinki
	Dressing viruses in tumor's clothing – new strategies in anti-tumor therapy
19:00	Boat trip on the Danube with dinner and DJ



FRIDAY 19 APRIL

09:00-10:00	Keynote INV23: Anne Galy, Inserm ART-TG laboratory Immune system: friend or foe in gene therapy
10:00-10:30	Coffee Break
10:30-12:30	Session 7: Pre-clinical and clinical gene therapy INV24: Giuliana Ferrari, SR Tiget, Milan Gene therapy for hemoglobinopathies: past, present and future INV25: Federico Mingozzi, Spark Therapeutics Translating in vivo gene therapies from bench to bedside INV26: Fatima Bosch, UAB, Barcelona A new horizon in gene therapy: Moving from the treatment of rare to highly prevalent diseases
12:30-13:30	Keynote INV27: Claire Booth, UCL London It is all about accessibility
13:30	Closing Alberto Auricchio, Hildegard Büning, Zoltan Ivics